Table 1 Clinical and hormonal parameters of the study population
From: Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight
Whole Cohort (n = 35) | Normal weight (n = 10) | Overweight/Obese (n = 25) | p* | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Baseline | 12–18 months | Last visit | Baseline | 12–18 months | Last visit | Baseline | 12–18 months | Last visit | ||
Sex (F/M) | 15/20 | 6/4 | 9/16 | 0.19 | ||||||
Age at diagnosis (years) mean ± SD | 43.4 ± 13.7 | 38.4 ± 15.3 | 45.4 ± 12.8 | 0.13 | ||||||
Type of adenoma micro/macro | 21/14 | 6/4 | 15/10 | ns | ||||||
Weight (kg) median ± IQR | 77.42 ± 24.62 | 82.0 ± 31.5 | 79.0 ± 25.75 | 61.5 ± 15.0 | 62.5 ± 8.0 | 66.0 ± 14.75 | 87.0 ± 36.55 | 94.0 ± 25.5 | 89.5 ± 20.0 | 0.0 |
BMI (kg/m2) median ± IQR | 28.0 ± 9.0 | 30.0 ± 9.0 | 28.0 ± 8.0 | 21.5 ± 5.0 | 23.0 ± 3.0 | 22.0 ± 6.0 | 30.0 ± 6.87 | 31.0 ± 7.5 | 30.0 ± 7.5 | 0.0 |
Cabergoline dose (mg) median ± IQR | 1.0 ± 1.5 | 1.0 ± 1.5 | 1.0 ± 0,87 | 1.0 ± 1.94 | 1.0 ± 1.5 | 0.87 ± 1.5 | ns | |||
Prolactin (ng/ml) median ± IQR | 137.7 ± 357.4 | 7.6 ± 9.6 | 6.5 ± 8.2 | 110.2 ± 93.0 | 11.2 ± 18.8 | 6.7 ± 10.9 | 199.0 ± 559.4 | 6.6 ± 7.3 | 6.3 ± 8.3 | ns |
GH (ng/ml) median ± IQR | 0.10 ± 0.52 | 0.21 ± 0.89 | 0.14 ± 0.53 | 0.19 ± 0.56 | 0.39 ± 2.64 | 0.50 ± 1.83 | 0.08 ± 0.47 | 0.19 ± 0.70 | 0.09 ± 0.20 | ns |
IGF-1 (ng/ml) median ± IQR | 144.0 ± 91.0 | 175.5 ± 85.0 | 158.0 ± 54.5 | 164.5 ± 139.0 | 181.5 ± 83.6 | 170.0 ± 48.7 | 132.0 ± 50.0 | 172.5 ± 88.0 | 156.0 ± 69.0 | 0.04# |
FT4 (pg/ml) median ± IQR | 7.4 ± 1.8 | 7.7 ± 1.4 | 8.1 ± 0.9 | 8.0 ± 1.8 | 8.0 ± 1.3 | 7.6 ± 0.9 | 7.3 ± 1.8 | 7.5 ± 1.5 | 8.2 ± 0.8 | ns |
Testosterone (pg/ml) median ± IQR | 1.38 ± 1.92 | 2.91 ± 1.07 | 3.20 ± 1.58 | 2.05 ± 3.39 | 2.77 ± 0.28 | 3.53 ± 1.73 | 1.38 ± 1.90 | 3.00 ± 1.44 | 3.20 ± 1.71 | ns |